Skip to content

Simona Parrinello keynote — the role of injury programs in gliomagenesis

Plenary keynote reframing glioma origin and progression in terms of wound-healing / injury-response transcriptional programs hijacked from normal CNS biology.

  • Speaker(s): Simona Parrinello, PhD
  • Affiliation: UCL Cancer Institute (Samantha Dickson Brain Cancer Unit), University College London
  • Anchor type: study (mechanism / biology keynote)
  • Day / session: Day 2 plenary (Tue Mar 24, 2026); title "The role of injury programs in gliomagenesis" confirmed on the public AACR Brain 26 program page
  • Status: post-meeting; details captured from AACR Brain 26 program notes and the confirmed keynote title; specific model-system and dataset specifics from the talk itself TBD pending abstract supplement

Headline finding

Plenary keynote arguing that glioblastoma growth, invasion, and recurrence are organized by injury-response / wound-healing transcriptional programs — the same programs that normal astrocytes, oligodendrocyte-lineage cells, and microglia run after CNS injury — co-opted by tumor cells and their TME. The framing places gliomagenesis on a continuum with reactive astrogliosis and CNS repair rather than treating it as a purely cell-autonomous oncogenic program, and predicts that surgery, radiation, and chemotherapy themselves create the injury context that drives a fraction of recurrence. Specific datasets and quantitative claims from the Brain 26 talk TBD.

Mechanism / methodology

Mouse models of glioma initiation and recurrence, paired with single-cell and spatial profiling of human glioma specimens, used to identify injury-program transcription factors and downstream effectors active in tumor cells, reactive astrocytes, and TAMs. The Parrinello lab's prior work on perivascular niche and stem-like glioma cell biology feeds the model. The keynote frames neurosurgical resection cavities and radiation-injured peritumoral tissue as a permissive niche for residual disease.

Mechanism / methodology deep dive

Underlying biology. Normal CNS injury (stab wound, stroke, demyelination) activates a stereotyped transcriptional program across astrocytes (reactive astrogliosis: GFAP, vimentin, LCN2), oligodendrocyte-lineage cells (OPC mobilization, PDGFRA re-expression), and microglia/TAMs (DAM-like states: TREM2, APOE, SPP1), governed by core TFs including STAT3, AP-1 (FOS/JUN), C/EBP family, and NF-κB. Parrinello's model: gliomagenesis hijacks these same programs — the MES-like glioma state in the Suva framework is, mechanistically, an injury-program state — and surgical / radiation injury at the resection cavity creates a permissive niche that selects for and expands injury-program-positive residual tumor cells.

Therapeutic design. Not a drug per se but a target-discovery framework. Tractable nodes nominated by the Parrinello lab and aligned work include: STAT3 (clinical-grade inhibitors available), C/EBPβ, AP-1 modulators, and injury-niche–restricted ligands (e.g., osteopontin/SPP1, CHI3L1). The peri-surgical / peri-RT window is the proposed clinical entry point — interrupting injury-program induction during the 2–4 week post-op window.

Resistance / failure modes. Injury-program activation is functionally redundant (multiple TF inputs converge on overlapping effector programs), making single-node pharmacology likely to be evaded; injury-program-positive cells are also intrinsically more resistant to chemo/RT (slow-cycling, stem-like).

Translational gaps. No clinical trial yet specifically targets the peri-surgical injury window with an injury-program inhibitor; biomarkers to identify injury-program-high tumors prospectively are unproven.

Where it fits in the corpus

  • AACR 2026: the injury-program framing dovetails with Suva-lineage cell-state biology and the Monje neural-circuit thread.
  • SITC 2026: TME / wound-healing programs intersect with TAM-targeting and microenvironment-reprogramming IO concepts.
  • Related Brain 26 entries: suva-glioma-cell-states.md, neuroscience-of-gliomas-tam.md, monje-gd2-cart-dipg.md.

Open questions

  • Which injury-program nodes are pharmacologically tractable in the peri-surgical window — and does interrupting them at the cavity actually reduce local recurrence?
  • How do injury programs intersect with the AC/MES-state axis (Suva framework) — is MES-like simply the injury-program state by another name, or genuinely distinct?